Moderna to Test Variant-Specific Vaccine Candidate
November 26 2021 - 04:10PM
Dow Jones News
By Josh Beckerman
Moderna Inc. discussed plans to address the Omicron Covid-19
variant, including a new variant-specific vaccine candidate known
as mRNA-1273.529.
The company said it is testing three vaccine booster candidates
against the variant.
The Omicron variant "includes mutations seen in the Delta
variant that are believed to increase transmissibility and
mutations seen in the Beta and Delta variants that are believed to
promote immune escape," the company said. "The combination of
mutations represents a significant potential risk to accelerate the
waning of natural and vaccine-induced immunity," Moderna said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 26, 2021 15:55 ET (20:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024